Synergistic effect of perfluorochemicals on BCNU chemotherapy. Experimental study in a 9L rat brain-tumor model.
In a study of the effect of adding perfluorochemicals to BCNU chemotherapy, 7 X 10(5) 9L tumor cells were implanted in the right cerebral hemisphere of Fischer 344 rats weighting about 100 gm each. On the 7th day after implantation, rats were given BCNU or Fluosol-43 (perfluorochemical artificial blood substitute), or a combination of the two, and the therapeutic effects of these treatments were studied. Mean survival time of control animals was 15.23 days +/- 2.84 days (standard deviation); in the group treated with Fluosol-43 and kept in an oxygen chamber (95% O2, 5% CO2), survival time was 15.30 +/- 2.11 days. The BCNU treatment alone and BCNU in rats kept in an oxygen chamber prolonged the mean survival time to 20.90 +/- 3.80 days and 21.10 +/- 2.14 days, respectively. Survival times in rats receiving BCNU plus Fluosol and breathing normal air, BCNU plus dextran-40 and breathing normal air, and BCNU plus dextran-40 in an oxygen chamber were 21.20 +/- 2.63 days, 22.90 +/- 1.52 days, and 22.20 +/- 1.79 days, respectively. On the other hand, treatment with BCNU plus Fluosol-43 in rats kept in an oxygen chamber resulted in a significant increase of mean survival time of 32.27 +/- 4.80 days (p less than 0.005). From these results, it seems likely that Fluosol-43 with oxygen might have a synergistic effect for BCNU chemotherapy in malignant brain tumors.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002330:Carmustine / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005466:Fluorocarbons / Q000627:therapeutic use*; D008297:Male; D009374:Neoplasms, Experimental / Q000188:drug therapy; D010100:Oxygen / Q000378:metabolism; D051381:Rats
D000970:Antineoplastic Agents; D005466:Fluorocarbons; C008807:perfluorotributylamine; D010100:Oxygen; D002330:Carmustine